Head-to-head evidence
adalimumab-adbm (Cyltezo) vs infliximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
infliximab · Remicade
Marketed by Johnson & Johnson and partners
NCT04205643 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, adequately powered (n=438 randomized into maintenance phase) Phase 3 trial with a hard clinical endpoint (clinical remission by modified Mayo score) that reached statistical significance in the favorable direction, satisfying the 'strong' definition.
Next expected readout: December 2026 · NCT06839820 (registry estimate)
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
infliximab · Remicade
Marketed by Johnson & Johnson and partners
NCT00094458 · Phase 3 · completed
This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).
Next expected readout: October 2026 · NCT05043870 (registry estimate)
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
infliximab · Remicade
Marketed by Johnson & Johnson and partners
NCT00269867 · Phase 3 · completed
This randomised, double-blind, placebo-controlled trial in 428 patients with rheumatoid arthritis (ATTRACT) reported ACR20 responses of 50-58% across the infliximab plus methotrexate regimens against 20% on placebo plus methotrexate at week 30 (P<0.001 for each regimen), on a validated measure of disease activity.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
infliximab · Remicade
Marketed by Johnson & Johnson and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · infliximab's landscape